Augmentation Therapy

Augmentation therapy consists of weekly intravenous (IV) infusions of Alpha-1 Antitrypsin derived from human plasma. It is used to increase the concentration of the protein in blood and lungs. Augmentation therapy is the only TGA-approved treatment for Alpha-1 Antitrypsin Deficiency. Your respiratory specialist can determine if you are an appropriate candidate for such therapy.

Drug and Other Therapies

This is among the most important types of medical therapy for the newly diagnosed individual with Alpha-1 Antitrypsin Deficiency. Although these are most relevant to lung-affected individuals, all Alphas have risks to their lungs. Some of the therapies listed are relevant for all Alpha-1 patients.

For information on Alpha-1 testing, please see page 5 of the AAA booklet.

Surgical Options

Organ Transplantation of the lung or liver


 The AAA has produced an information booklet which contains more detail about A1AD, and a poster for raising awareness. You can access the booklet and poster by clicking on the images below. The poster may be printed locally in A3 or A4 size. Please encourage your family doctor or respiratory physician to put a poster on display in the surgery or patient waiting area! For more information about A1AD, see our Links section.